Investigational drug · Phase 3
matched to Cagrilintide
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Overweight, Obesity, Type 2 Diabetes.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
27
Any phase or sponsor naming "matched to Cagrilintide"
First trial start
2025
Nov 5, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "matched to Cagrilintide", any sponsor or status.
- Phase 316
Conditions studied
As listed on its trial records.
- Overweight
- Obesity
- Type 2 Diabetes
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "matched to Cagrilintide" as an intervention, largest first.
- REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05669755 · 7,101 participants · Start Mar 1, 2023 · Primary completion Sep 1, 2027
Drug: Cagrilintide; Semaglutide and 1 more · For: Cardiovascular Disease
Sites: Birmingham, Alabama; Montgomery, Alabama; Scottsdale, Arizona · 633 sites in all
- A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05567796 · 3,400 participants (planned) · Start Nov 1, 2022 · Primary completion Oct 30, 2024
Drug: Cagrilintide; Semaglutide and 2 more · For: Obesity
Sites: Birmingham, Alabama; Los Angeles, California; Aurora, Colorado · 256 sites in all
- A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06065540 · 2,734 participants · Start Sep 27, 2023 · Primary completion Nov 19, 2025
Drug: Cagrilintide; Semaglutide and 2 more · For: Type 2 Diabetes Mellitus
Sites: Birmingham, Alabama; Pelham, Alabama; Phoenix, Arizona · 405 sites in all
- A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and PlaceboPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06131372 · 626 participants · Start Apr 1, 2024 · Primary completion Sep 24, 2025
Drug: Cagrilintide; Semaglutide and 1 more · For: Chronic Kidney Disease; Type 2 Diabetes; Obesity
Sites: Concord, California; Fresno, California; Palm Springs, California · 129 sites in all
- A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07011667 · 609 participants · Start Jun 3, 2025 · Primary completion Mar 1, 2027
Drug: CagriSema (Cagrilintide B and Semaglutide I); Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) · For: Obesity
Sites: Costa Mesa, California; San Diego, California; Walnut Creek, California · 47 sites in all
- A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07253285 · 460 participants (planned) · Start Jan 8, 2026 · Primary completion Mar 20, 2030
Drug: Cagrilintide; Semaglutide and 2 more · For: Overweight; Obesity
Sites: Escondido, California; Hollywood, Florida; Jacksonville, Florida · 121 sites in all
- A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With ObesityPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06780449 · 400 participants (planned) · Start Feb 10, 2025 · Primary completion Aug 28, 2028
Drug: Cagrilintide; Semaglutide and 2 more · For: Obesity
Sites: Covina, California; Walnut Creek, California; New Haven, Connecticut · 36 sites in all
- A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose WeightPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05813925 · 331 participants · Start Apr 3, 2023 · Primary completion Jan 17, 2025
Drug: Cagrilintide; Semaglutide and 1 more · For: Obesity or Overweight
Sites: Koriyama-shi, Fukushima, Japan; Yamato-shi, Japan; Miyazaki, Japan · 28 sites in all
- Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With CagrilintidePivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07220759 · 330 participants (planned) · Start Nov 5, 2025 · Primary completion May 12, 2027
Drug: Cagrilintide; Placebo (matched to Cagrilintide) · For: Overweight; Obesity; Type 2 Diabetes
Sites: Birmingham, Alabama; Montgomery, Alabama; Tucson, Arizona · 67 sites in all
- A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose WeightPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06388187 · 300 participants · Start Jun 24, 2024 · Primary completion Apr 22, 2026
Drug: Cagrilintide; Semaglutide and 1 more · For: Obesity
Sites: Costa Mesa, California; Plantation, Florida; Indianapolis, Indiana · 25 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Overweight
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novo Nordisk.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.